Changes in Skin Myco- and Microbiome After Lebrikizumab Treatment
Key facts
- Where
- Copenhagen, DenmarkSee the site
Where in Denmark
- Dermatology Department BispebjergCopenhagen, DenmarkTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University Hospital Bispebjerg and Frederiksberg
- Trial code
- NCT07807228
- Record updated
- 8 September 2026
- Original description
The goal of this observational study is to characterize the skin myco- and microbiome of patients with atopic dermatitis before and after initiation of treatment with lebrikizumab. The main questions it aims to answer are:Read full original descriptionShow less
Changes in Fungal Mycobiome, Bacterial Microbiome, and Abundance of Staphylococcus Species After Lebrikizumab Treatment - a Prospective Multicenter Observational Cohort Study
The goal of this observational study is to characterize the skin myco- and microbiome of patients with atopic dermatitis before and after initiation of treatment with lebrikizumab. The main questions it aims to answer are:
Does the skin mycobiome change with treatment? Does the skin microbiome change with treatment? Does the abundance of Staphylococcus species change with treatment?
Inclusion: Adults ≥18 years diagnosed with atopic dermatitis and initiating treatment with lebrikizumab.
Exclusion: Previous treatment with lebrikizumab; Current treatment with other biologics or JAK-inhibitors; Hypersensitivity to lebrikizumab or any of its constituents; Active helminth infection; Pregnancy or breastfeeding.